Logotype for Moleculin Biotech Inc

Moleculin Biotech (MBRX) investor relations material

Moleculin Biotech Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Moleculin Biotech Inc
Q2 2025 earnings summary13 Aug, 2025

Executive summary

  • Conducting pivotal MIRACLE Phase 3 trial for Annamycin in relapsed/refractory AML, with interim unblinding expected by end of 2025 and further unblinding in H1 2026.

  • Expanded MIRACLE trial to over 35 global sites, including the EU and Georgia, with 8 subjects treated as of July 25, 2025.

  • Achieved positive topline results in Phase 1B/2 STS lung metastases trial, showing median OS of 13.5 months in heavily pretreated patients.

  • Annamycin has shown no evidence of cardiotoxicity in 84 subjects across five clinical trials.

  • Advanced patent protection for Annamycin in the US and EU, with exclusivity to 2040.

Financial highlights

  • Net loss of $7.6 million for Q2 2025, compared to $4.3 million in Q2 2024; net loss of $14.1 million for the six months ended June 30, 2025.

  • Research and development expenses decreased to $3.6 million in Q2 2025 from $4.1 million in Q2 2024, mainly due to reduced clinical trial activity.

  • General and administrative expenses were $2.1 million in Q2 2025, flat year-over-year.

  • Cash and cash equivalents were $7.6 million as of June 30, 2025, up from $4.3 million at December 31, 2024, due to financing activities.

  • Recorded a $9.6 million gain from change in fair value of warrant liability in Q2 2025.

Outlook and guidance

  • Cash on hand is expected to fund operations into Q4 2025; an additional $10 million in funding is needed to support operations and the MIRACLE trial into Q1 2026.

  • Interim unblinding of MIRACLE trial data targeted for H2 2025, with further unblinding in H1 2026.

  • Plan to initiate pediatric AML trial in 2027 and submit NDA for Annamycin in 2028.

  • Actively seeking additional funding through equity, debt, partnerships, or delaying planned cash outlays.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Moleculin Biotech earnings date

Logotype for Moleculin Biotech Inc
Q3 202512 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Moleculin Biotech earnings date

Logotype for Moleculin Biotech Inc
Q3 202512 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company aiming to develop treatments addressing some of the most challenging diseases in the world, including highly resistant cancers and viruses. The company's lead drug, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance with minimal cardiotoxicity, currently under development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, Moleculin is working on WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies, alongside WP1220 for cutaneous T-cell lymphoma and WP1122, aimed at treating COVID-19 and glioblastoma multiforme, among other conditions. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage